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Background: Ovaleap® (follitropin alfa), a recombinant human follicle-stimulating hormone intended for use in
controlled ovarian stimulation in women undergoing assisted reproductive technologies (ART), showed therapeutic
equivalence to Gonal-f® in a multinational, multicenter, randomized, controlled, assessor-blind phase 3 Main Study.
The current study examined safety, including immunogenicity, and efficacy of Ovaleap® in an open-label, uncontrolled,
follow-up treatment period of up to 2 additional treatment cycles in patients who did not become pregnant in the
phase 3 Main Study.
Methods: Patients with negative biochemical or clinical pregnancy in the phase 3 Main Study, regardless of treatment
group (ie, Ovaleap® or Gonal-f®), were eligible to participate. Patients received Ovaleap® (Merckle Biotec GmbH, Ulm,
Germany) for up to 2 additional cycles, administered using a reusable semi-automated pen device. The primary
objective was the assessment of safety, including adverse events (AEs), ovarian hyperstimulation syndrome
(OHSS), and anti-drug antibodies. Tolerability, patient satisfaction with the Ovaleap® pen device, and efficacy
outcomes (as evaluated in the Main Study) were also assessed.
Results: One hundred forty-seven patients were included in cycle 2, and 61 patients were included in cycle 3. In cycles 2
and 3, 10.9 % (16/147) and 6.6 % (4/61) of patients experienced treatment-emergent AEs (TEAEs), respectively. Three
serious TEAEs (ie, appendicitis, OHSS, and borderline ovarian tumor) were reported and successfully resolved. The OHSS
TEAE was the only OHSS reported in the study (0.7 % [1/147]). Positive findings on anti-drug antibody assays in 6 serum
samples did not show neutralizing activity or clinical relevance in biochemical pregnancy rate. No hypersensitivity reaction
occurred. Most patients reported “very good”/“good” local tolerability. All patients were “very confident”/“confident” about
dose accuracy and correctness of the injection. They all found use of the pen “very convenient”/“convenient” and were all
“very satisfied”/“satisfied” with the pen device. Efficacy outcomes were consistent with the phase 3 Main Study.
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Conclusions: These findings further support the safety, including immunogenicity, and efficacy of Ovaleap® for
stimulation of follicular development in infertile women undergoing ART. The findings support continued use of Ovaleap®
for multiple cycles or a switch to Ovaleap® if pregnancy is initially not achieved with Gonal-f®.
Trial registration: EudraCT number: 2009-017674-20. Current controlled trials register number: ISRCTN74772901.
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Recombinant human follicle-stimulating hormone (r-hFSH)
provides an ovulation induction or ovarian stimulation
treatment option for women with infertility being treated
with assisted reproductive technologies (ART). The produc-
tion of r-hFSH in mammalian cells using recombinant
DNA technology, as compared with urinary-derived go-
nadotropin preparations, allows for greater availability of a
biochemically pure FSH preparation, without urinary pro-
tein contaminants and with reduced product variability that
can be associated with different urinary purification
techniques [1, 2]. Additionally, r-hFSH has the potential
benefit of reduced risk of immunological reactions due
to the absence of impurities [1, 3]. Low immunogenicity
also allows for subcutaneous (SC) administration [2].
XM17 (Ovaleap®; follitropin alfa), an r-hFSH manu-
factured in Chinese hamster ovary cells, is intended
for use in controlled ovarian stimulation in women
undergoing ART, for treatment of anovulation—in-
cluding polycystic ovarian syndrome, and for stimula-
tion of spermatogenesis. Ovaleap® (Merckle Biotec
GmbH, Ulm, Germany), approved by the European
Medicines Agency in 2013 [4], was developed as a bio-
similar (ie, this agent demonstrated similarity in physi-
cochemical characteristics, efficacy, and safety [5]) to
Gonal-f®, following clinical development guidelines
established by the Committee for Medicinal Products
for Human Use [6]. Two pharmacokinetic studies of
Ovaleap® conducted in healthy female subjects demon-
strated dose-proportionality and bioequivalence to Gonal-f®,
as indicated by peak plasma concentration (Cmax) and area
under the concentration-time curve (AUC0-t) [7, 8]. A
multinational, multicenter, randomized, controlled,
assessor-blind phase 3 patient-study—henceforth to be
termed “Main Study”—compared efficacy and safety
endpoints of Ovaleap® and Gonal-f® in infertile women
using ART and demonstrated therapeutic equivalence
[9]. The mean ± SD numbers of oocytes retrieved (pri-
mary efficacy endpoint) were 12.2 ± 6.7 for Ovaleap®
and 12.1 ± 6.7 for Gonal-f®. Treatment-emergent ad-
verse event (TEAE) profiles were similar in patients
receiving Ovaleap® and Gonal-f®.
The current study covers an open-label, uncontrolled,
follow-up treatment period to the Main Study. The
open-label treatment period consisted of up to 2additional Ovaleap® treatment cycles following the Main
Study for women who did not become pregnant in the
Main Study. The open-label follow-up study’s primary
objective was to assess Ovaleap® safety, including im-
munogenicity, during second and third treatment cycles
and following the switch from Gonal-f® in the Main
Study. Secondary objectives were to assess number of
oocytes retrieved and total Ovaleap® dose.Methods
Patient population
Infertile but otherwise healthy, normal gonadotropic
women with regular menstrual cycles, aged 18 to
37 years, were eligible to participate in the multinational,
multicenter, randomized, controlled, assessor-blinded,
parallel-group phase 3 Main Study that compared Ova-
leap® and Gonal-f® in a long gonadotropin-releasing hor-
mone (GnRH) agonist protocol [9]. Study inclusion and
exclusion criteria for the phase 3 Main Study have been
previously described (Appendix 1). Patients who had a
negative biochemical or clinical pregnancy following the
phase 3 Main Study, regardless of their treatment group
(ie, Ovaleap® or Gonal-f®), were eligible to participate in
the follow-up study. The open-label follow-up study in-
cluded patients from 19 centers in 5 countries.Study design
The study protocol and informed consent documents
were approved by the relevant independent ethics com-
mittees. The study was conducted in accordance with
the Good Clinical Practice Consolidated Guideline, ac-
cording to the International Conference on Harmonisa-
tion and the Declaration of Helsinki (1996). Regardless
of their r-hFSH treatment in the Main Study, all patients
in the open-label follow-up study received Ovaleap® for
up to 2 additional cycles following completion of the
Main Study (Fig. 1). Prior to participation in the open-
label follow-up study, at least 1 spontaneous cycle was
required between the negative biochemical or clinical
pregnancy in the Main Study and the start of cycle 2,
the second ovarian stimulation cycle for the patient. The
same applied for the third ovarian stimulation cycle
(cycle 3). Throughout the open-label follow-up study,
the investigator and the embryologist remained blinded
AB
Fig. 1 Study Design Showing Cycle 2 (Panel A) and Cycle 3 (Panel B) of Ovaleap® Treatment. a Ovaleap® Cycle 2. b Ovaleap® Cycle 3. d, days;
hCG, human chorionic gonadotropin; V1, Visit 1; V2, Visit 2; V3, Visit 3; V4, Visit 4; W 12, Week 12. aThe duration of Ovaleap® treatment was at the
discretion of the investigator
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in the Main Study.
Cycle 2 and cycle 3 of Ovaleap® treatment each in-
cluded 4 study visits, and treatment was started at Visit
1. Pituitary down-regulation was performed at the dis-
cretion of the investigator, using GnRH agonists, includ-
ing busereline, nafarelin, goserelin, and triptorelin (cycle
2 = 68.7 % [101/147] of patients; cycle 3 = 70.5 % [43/61]
of patients) or GnRH antagonists, including cetrorelix
and ganirelix (cycle 2 = 27.2 % [40/147] of patients; cycle
3 = 27.9 % [17/61] of patients). Final maturation of oo-
cytes was triggered by human chorionic gonadotropin
(hCG) injection. Vaginal ultrasound examination was
performed to count the number of follicles prior to hCG
administration. hCG was withheld if there was a risk of
OHSS, as indicated by estradiol level >5500 pg/mL and/
or >40 follicles on ultrasound. Oocyte retrieval was
performed at Visit 2, 34 to 37 h after hCG administra-
tion, and in vitro fertilization (IVF) and/or intra-cytoplasmic sperm injection (ICSI) was completed.
Outcome categorization (without pronucleus [PN], 1
PN, 2 PNs, or ≥3 PNs) was assessed at 16 to 20 h after
incubation. At this time, oocyte quality also was
assessed using the Z score [10]. The morphology of the
2 PN oocytes was graded Z1 (best quality) to Z4 (worst
quality), based on the number, size, distribution, and
alignment of nuclei in the PN. Embryo transfer oc-
curred at the discretion of the embryologist and investi-
gator. At Visit 3, approximately 16 to 19 days following
oocyte retrieval, biochemical pregnancy testing (β-hCG
test) and end-of-study assessments were completed.
For some patients who did not become pregnant in
cycle 2, Visit 4 of cycle 2 was performed at the same
time as Visit 1 of cycle 3.
Patients were treated individually at the discretion of
the investigator. The starting dose of Ovaleap® was de-
termined by the investigator, with the limitation that
doses above 450 IU/day were not recommended. The
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ments (up or down) to achieve adequate follicular devel-
opment, based on clinical aspects, serum estradiol levels,
and/or ultrasound examinations. Dose adjustments
were allowed every 3 to 5 days through Day 20 in in-
crements or multiples of 37.5 IU (but no more than
150 IU) to a maximum of 450 IU/day. The treatment
phase was up to 20 days per cycle. The investigator
selected the drugs and regimen for pituitary down-
regulation, the hCG for ovulation induction, and any
luteal support. The first dose of Ovaleap® was adminis-
tered at the investigator’s study site, and subsequent daily
doses were self-administered by subjects. Ovaleap® was
supplied in glass cartridges containing 900 IU in 1.5 mL
solution and was administered SC from a reusable semi-
automated pen device.
Safety and immunogenicity assessments
The primary objective of the open-label follow-up
study was the assessment of safety, including immuno-
genicity. Assessments included AEs, OHSS, overall and
local tolerability, laboratory variables (ie, clinical
chemistry, hematology, and endocrinology), vital signs
(ie, blood pressure and heart rate), clinical picture, and
immunogenicity via antibody testing. All AEs were
considered treatment-emergent AEs and were defined
as any unfavorable or unintended sign, symptom, or
disease temporally associated with the use of Ovaleap®,
whether or not it was considered related to the use of
Ovaleap®. Serious TEAEs were defined as AEs that
resulted in death, were life-threatening, required in-
patient hospitalization or prolongation of existing
hospitalization, resulted in persistent or significant dis-
ability/incapacity, were a congenital anomaly/birth de-
fect, or were judged an important medical event that
may have jeopardized the patient or may have required
medical intervention to prevent one of the listed ser-
ious TEAE criteria. Intensity was assessed for both
serious and non-serious AEs as mild, moderate, or se-
vere. The investigator assessed the causal relationship
of the AE to Ovaleap® as probable, possible, unlikely, not
classifiable, or not related. The relationship of treatment-
emergent adverse drug reactions (TEADRs) to Ovaleap®
was assessed by the investigator as probable, possible, un-
likely, not classifiable, or missing. AEs of special interest
included OHSS, ectopic pregnancy, pregnancy loss, and
embolic and thrombotic events. OHSS severity was de-
fined as moderate, severe, or life-threatening, using cri-
teria from Papanikolaou and Navot [11, 12]. AEs were
documented from the time of study consent until 30 days
after the last Ovaleap® administration.
Immunogenicity blood samples were obtained for
anti-drug antibody testing before Ovaleap® administra-
tion, on the day of oocyte retrieval, and 3 monthsafter the final Ovaleap® administration, regardless of
the number of cycles. Serum samples were assessed
for the presence of both anti-FSH antibodies and
anti-N-glycolylneuraminic acid (anti-Neu5Gc) anti-
bodies using validated assays at a central laboratory.
The assay detected antibodies against the whole Ova-
leap® molecule as well as protein moiety and Neu5Gc
moiety. Biological relevance was assessed through a
cell-based antibody assay to detect neutralizing re-
activity. All assays were fully validated in bioanalytical
laboratories.
Overall tolerability was assessed by patients and
investigators at the end-of-study visit using a 5-point
verbal rating scale (1 = very good, 2 = good, 3 = mod-
erate, 4 = poor, 5 = very poor). Patients assessed their
local tolerability (ie, injection-site pain and reactions)
to Ovaleap® administration using daily diaries.
Injection-site pain was rated from 0 (no pain at all)
to 10 (the most severe pain) following each injection.
Patients recorded the presence of any injection-site
reactions of redness, bruising, swelling, burning, or
skin irritation, and they rated the intensity as no re-
action, mild, moderate, or severe. Possibly clinically
significant laboratory values were defined as >3 times
the upper limit or <1/3 the lower limit of the refer-
ence range.
Pen device satisfaction
Patient satisfaction with the Ovaleap® reusable semi-
automated pen device was examined using a 7-question
questionnaire based on Somkuti (2006) [13]. Subjects
rated their confidence in accurately preparing the daily
dose (scale: 1 = very confident, 2 = confident, 3 = not
confident); their confidence in injecting the correct daily
dose (scale: 1 = very confident, 2 = confident, 3 = not
confident); the ease of understanding the written in-
structions (scale: 1 = very easy, 2 = easy, 3 = not easy); the
number of times they asked the doctor’s office to explain
the administration of the daily dose (>4 times, 4 times, 3
times, twice, once, never); the overall ease of use of the
pen (scale: 1 [easiest] to 10 [most difficult]); the conveni-
ence of administering study medication with the pen
(scale: 1 = very convenient, 2 = convenient, 3 = not con-
venient); and their satisfaction with administering study
medication with the pen (scale: 1 = very satisfied, 2 = sat-
isfied, 3 = not satisfied).
Secondary endpoints
The total Ovaleap® dose and duration of stimulation; num-
ber of follicles >14 mm; number of follicles ≤10 mm, >10–
14 mm, >14–17 mm, and >17 mm on the day of hCG
administration; cancellation rate (ie, premature study end
due to no oocytes retrieved); number of oocytes retrieved;
oocyte quality; biochemical pregnancy rate; and ongoing
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mined as the mean of 2 diameters measured on the per-
pendicular axes in the largest sagittal plane of the follicle.
The biochemical pregnancy rate was calculated per started
cycle, per oocyte retrieval in the cycle, and per embryo
transfer in the cycle. The ongoing pregnancy rate was cal-
culated per embryo transferred as the following: the num-
ber of pregnant patients divided by the number of patients
who had an embryo transfer × 100.
Data analysis
The planned open-label follow-up study analyses were
descriptive (eg, mean ± SD, median, range, percentages)
and exploratory. These analyses included all patients
who received at least 1 dose of Ovaleap® during the
open-label follow-up study. Analyses were conducted
separately for cycle 2 and cycle 3 and for the combined
cycles. Results are reported according to the treatment
received in the phase 3 Main Study (Ovaleap® versus
Gonal-f® patient groups) and overall. SAS version 9.2
was used for all analyses.
Results
One hundred and seventy-seven patients from the
phase 3 Main Study did not have a clinical pregnancy
and were eligible for enrollment (Fig. 2). A total of
155 patients were enrolled, and 147 patients metFig. 2 Patient Dispositioninclusion/exclusion criteria and received at least 1
dose of Ovaleap®. Cycle 2 included 147 patients, and
cycle 3 included 61 patients from study centers across
5 countries (Appendix 2). Demographic characteristics
were comparable between the patients who had re-
ceived Ovaleap® versus Gonal-f® during the phase 3
Main Study in both cycle 2 and cycle 3 of the open-
label follow-up study (Table 1).
Safety and immunogenicity
In the Main Study, the overall TEAE frequency was 47/
299 (15.7 %) patients. None of the patients who entered
the open-label follow-up study had ongoing AEs from
the Main Study. The frequency of TEAEs was low after
treatment in cycle 2 and cycle 3 (Appendix 3); 16/147
(10.9 %) patients experienced TEAEs in cycle 2, 4/61
(6.6 %) patients experienced TEAEs in cycle 3, and 19/
147 (12.9 %) patients experienced TEAEs in the com-
bined cycles 2 and 3. Only 1 patient experienced TEAEs
in both cycle 2 and cycle 3. In cycles 2 and 3 combined,
the overall frequencies of TEAEs were comparable in pa-
tients previously treated with Ovaleap® versus Gonal-f®
in the Main Study (11.3 % versus 14.9 %, respectively).
All TEAEs resolved.
Among TEAEs categorized as non-serious, back pain
rated as severe intensity was reported in 1 patient in
cycle 2. Two TEAEs were categorized by the
Table 1 Demographic Characteristicsa
Previous Treatment in Main Study
Total Group Ovaleap® Gonal-f®
Cycle 2 N = 147 N = 80 N = 67
Age, years
Mean (SD) 31.6 (3.3) 31.4 (3.4) 31.9 (3.0)
Age, n (%)
< 30 years 37 (25.2) 23 (28.8) 14 (20.9)
30 to 34 years 77 (52.4) 42 (52.5) 35 (52.2)
> 34 years 33 (22.4) 15 (18.8) 18 (26.9)
Weight, kg
Mean (SD) 63.2 (9.4) 63.1 (9.8) 63.4 (8.8)
BMI, kg/m2
Mean (SD) 22.7 (2.8) 22.7 (2.8) 22.6 (2.8)
Smoker, n (%) 20 (13.6) 13 (16.3) 7 (10.4)
Alcohol consumption, n (%) 25 (17.0) 18 (22.5) 7 (10.4)
Cycle 3 N = 61 N = 34 N = 27
Age, years
Mean (SD) 31.6 (3.2) 31.1 (3.5) 32.3 (2.8)
Age, n (%)
< 30 years 13 (21.3) 10 (29.4) 3 (11.1)
30 to 34 years 34 (55.7) 19 (55.9) 15 (55.6)
> 34 years 14 (23.0) 5 (14.7) 9 (33.3)
Weight, kg
Mean (SD) 63.5 (8.9) 62.5 (8.2) 64.7 (9.7)
BMI, kg/m2
Mean (SD) 23.0 (2.9) 22.8 (2.8) 23.3 (3.1)
Smoker, n (%) 11 (18.0) 7 (20.6) 4 (14.8)
Alcohol consumption, n (%) 13 (21.3) 8 (23.5) 5 (18.5)
BMI body mass index; SD standard deviation
aReasons for and duration of infertility were comparable between the Ovaleap® and Gonal-f® groups in the Main Study [9]
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mild injection-site erythema, pruritus, and hematoma
and 1 mild lower abdominal pain. Three serious TEAEs
were reported: 1 appendicitis, 1 OHSS, and 1 border-
line ovarian tumor. The appendicitis was assessed as
unrelated to study medication and resolved but resulted
in premature study discontinuation for the patient. The
OHSS occurred in cycle 2 and led to hospitalization.
This was the only OHSS reported in the follow-up
study (0.7 % [1/147]). It was assessed as a TEADR
probably related to study medication and resolved. The
borderline ovarian tumor experienced by 1 patient was
diagnosed during planned laparoscopy, a standard pro-
cedure following 2 unsuccessful IVF procedures. It was
assessed as a TEADR unlikely related to study medica-
tion. The AE outcome was reported as recovered withright ovariectomy and salpingectomy, left partial salpin-
gectomy, omentectomy, and appendectomy. There
were no deaths or other serious or significant AEs and
no ectopic pregnancy, pregnancy loss, or embolic or
thrombotic events.
A total of 485 blood samples from 147 patients
participating in the open-label follow-up study were
analyzed for immunogenicity. Only 6 patients had
confirmed positive findings against Ovaleap® and
Neu5Gc during cycle 2. Four patients had pre-existing
anti-drug antibodies against Neu5Gc in cycle 2, and
the remaining 2 patients developed antibodies against
Neu5Gc. None of the samples showed neutralizing
activity; therefore, no patient developed neutralizing
antibodies. Biochemical pregnancy rates were compar-
able between patients who had antibodies against
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and patients who did not, indicating the positive find-
ings were not clinically relevant. None of the patients
showed a hypersensitivity reaction during the study.
Potentially clinically significant laboratory values
were obtained in 2 patients, including below refer-
ence range alanine aminotransferase values during
cycle 3 in 1 patient and depressed basophil values at
the start of cycle 2 for 1 patient. No TEAEs related
to vital signs were reported, and results for labora-
tory safety variables and vital signs did not raise any
safety concerns.
Tolerability
All patients rated Ovaleap® overall tolerability as “very
good” or “good.” Investigators rated tolerability as “very
good” or “good” in all but 4 patients who were rated as
showing moderate tolerability.
Patient reports of local tolerability included ratings
of injection-site pain (scale ranging from 0 [no pain
at all] to 10 [most severe pain]) at each treatment
day. Apart from 1 patient who reported a rating of 6
on a given treatment day, mean scores were low, be-
ing not more than 1 on all but 2 treatment days (re-
spectively, 1.1 and 1.7). In cycle 2, most patients
(>80 %) did not report any injection-site reactions (ie,
bruising, burning, redness, skin irritation, and swell-
ing) after the first injection. Across all injections in
cycle 2, moderate reactions were reported in 4 pa-
tients and a severe reaction was only reported for
bruising in 1 patient on 1 stimulation day. In cycle 3,
mild reactions were reported in 11 patients and mod-
erate reactions in 3 patients. Severe injection-site
reactions were reported in 7 patients on a single
stimulation day.
Satisfaction with pen device
In cycle 2, the mean rating for overall ease of use of
the Ovaleap® injection pen was 1.4 (scale ranging
from 1 [easiest] to 10 [most difficult]) (Table 2). All
patients were “very confident” or “confident” about
the accuracy of the dose (83.2 % and 16.8 %, respect-
ively) and about correctness of the injection (83.9 %
and 16.1 %, respectively). The instructional text for
the pen was rated “very easy” to understand by
75.5 % (108/143) of patients and “easy” by 23.8 %
(34/143) of patients. The frequency of additional ex-
planation for how to use the pen was reported as
“never” or “one time” by 98.6 % (141/143) of patients.
All patients found the pen “very convenient” or “con-
venient” (76.9 and 23.1 %, respectively) and were
“very satisfied” or “satisfied” (83.2 and 16.8 %, re-
spectively) with the pen. In cycle 3, results were
slightly more favorable than for cycle 2, which can beexpected due to increasing familiarization with the in-
jection pen (data not shown).
Secondary endpoints
The mean ± SD (median) total dose of Ovaleap® in
cycle 2 was 1998 ± 771 (1875) IU, and in cycle 3, it was
2113 ± 939 (1875) IU; the median treatment duration
for both cycles 2 and 3 was 10 days (Table 3). The
mean ± SD number of follicles >14 mm on the hCG
injection day in cycle 2 was 10.0 ± 5.6 and in cycle 3
was 11.9 ± 5.4 (Appendix 4). At least 1 oocyte was har-
vested in 99.3 % (146/147) of patients in cycle 2 and
98.4 % (60/61) of patients in cycle 3. The mean ± SD
(median [range]) number of oocytes was 12.1 ± 5.9
(11.0 [2.0 to 36.0]) in cycle 2 and 13.5 ± 6.5 (12.0 [3.0
to 33.0]) in cycle 3 (Table 3). Oocyte quality was simi-
lar to that observed in the Main Study (Appendix 5).
The median number of embryos obtained per patient
was 3 (range 0 to 19) in cycle 2 and 4 (range 2 to 15) in
cycle 3. The median number of embryos transferred in
cycle 2 was 2 (range 0 to 4) and in cycle 3 was 2 (range
1 to 4). Biochemical pregnancy rates, based on the β-
hCG test, were 31 % during both cycle 2 and cycle 3
(46/147 and 19/61, respectively), and the overall rate for
combined cycle 2 and 3 was 42.9 % (63/147) (Table 4).
Two of the patients with biochemical pregnancy in cycle
2 did not have clinical pregnancy and went on to be
treated with Ovaleap® in cycle 3. Including only those
patients with embryo transfer, the ongoing pregnancy
rate in cycle 2 was 25.9 % (37/143), in cycle 3 was
21.7 % (13/60), and in combined cycles 2 and 3 was
34.7 % (50/144).
In cycle 2, one patient terminated the study early
due to the AE appendicitis, resulting in an overall
cancellation rate prior to oocyte retrieval of 0.7 % (1/
147). In cycle 3, one patient terminated the study early
due to menstrual cycle disorders and no response to
Ovaleap®, resulting in an overall cancellation rate of
1.6 % (1/61).
Discussion
The safety and efficacy findings in this open-label, non-
controlled single therapy follow-up study involving up
to 2 additional Ovaleap® treatment cycles beyond the
Main Study were comparable to the outcomes in the
Main Study, which was a multinational, multicenter,
randomized, controlled, assessor-blind phase 3 com-
parison of Ovaleap® and Gonal-f® in patient groups of
infertile women using ART [9]. Overall frequencies of
TEAEs in combined cycle 2 and cycle 3 in the open-
label follow-up study were low and comparable be-
tween patient groups treated with Ovaleap® or Gonal-f®
in the phase 3 Main Study. There were no clinically
relevant differences in safety results and no new or
Table 2 Patient Satisfaction With the Ovaleap® Pen at the End of Cycle 2
Previous Treatment in Main Study
Question Total Group Ovaleap® Gonal-f®
N = 143 N = 77 N = 66
n (%) n (%) n (%)
Overall ease of usea
Mean (SD) 1.4 (1.1) 1.2 (0.5) 1.5 (1.4)
Confidence about accurate dose
Very confident 119 (83.2) 66 (85.7) 53 (80.3)
Confident 24 (16.8) 11 (14.3) 13 (19.7)
Not confident 0 0 0
Confidence about correct injection
Very confident 120 (83.9) 67 (87.0) 53 (80.3)
Confident 23 (16.1) 10 (13.0) 13 (19.7)
Not confident 0 0 0
Plainness of instructional text
Very easy 108 (75.5) 58 (75.3) 50 (75.8)
Easy 34 (23.8) 19 (24.7) 15 (22.7)
Not easy 1 (0.7) 0 1 (1.5)
Frequency of explanation of administration
Never 87 (60.8) 52 (67.5) 35 (53.0)
Once 54 (37.8) 25 (32.5) 29 (43.9)
Twice 2 (1.4) 0 2 (3.0)
Convenience of pen usage
Very convenient 110 (76.9) 56 (72.7) 54 (81.8)
Convenient 33 (23.1) 21 (27.3) 12 (18.2)
Not convenient 0 0 0
Satisfaction with administration
Very satisfied 119 (83.2) 63 (81.8) 56 (84.8)
Satisfied 24 (16.8) 14 (18.2) 10 (15.2)
Not satisfied 0 0 0
aThe overall ease of use of the pen was rated using a scale ranging from 1 (easiest) to 10 (most difficult)
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ings of anti-drug antibodies against Ovaleap®, which
were characterized as low-titer and predominantly pre-
existing Neu5Gc-specific antibodies, lacked clinical
relevance. The samples did not show neutralizing activ-
ity, patients did not differ in rates of biochemical preg-
nancy, and no hypersensitivity reactions occurred. An
overview of the highly sensitive immunogenicity assays
and outcomes in the Main Study and the follow-up
study indicated lack of clinical relevance [14]. The
mean number of oocytes retrieved and oocyte quality
in the current study were similar to the Main Study [9]
and were comparable to those in prior studies of
Gonal-f® [15–20]. Additionally, a greater percentage ofpatients reported satisfaction with the Ovaleap® injection
pen device than those that have been reported in studies
of satisfaction and preference with other pen devices
(100 % versus 80 % and 84 %, respectively) [21, 22].
Altogether, the study findings, including examination of
immunogenicity, support the safety and efficacy of a
switch to Ovaleap® if pregnancy is initially not achieved
with Gonal-f® and suggest a course of up to 3 cycles of
treatment with Ovaleap® is safe and well tolerated by
patients.
Total dose of r-hFSH (Ovaleap® or Gonal-f®) in-
creased from the first treatment cycle in the Main
study to the second and third Ovaleap® cycles in the
current study. This is consistent with previous studies
Table 3 Total Ovaleap® Dose and Duration of Stimulation and Number of Oocytes Retrieved
Previous Treatment in Main Study
Total Group Ovaleap® Gonal-f®
Cycle 2 N = 147 N = 80 N = 67
Total Ovaleap® dose, IU
Mean (SD) 1998 (771) 1925 (706) 2086 (840)
Median (range) 1875 (450–4313) 1763 (1013–3750) 2025 (450–4313)
Duration of Ovaleap® stimulation, days
Mean (SD) 9.9 (1.8) 9.7 (1.8) 10.0 (1.9)
Median (range) 10.0 (4.0–14.0) 10.0 (5.0–14.0) 10.0 (4.0–14.0)
Number of oocytes retrieveda
Mean (SD) 12.1 (5.9) 12.0 (5.8) 12.1 (6.0)
Median (range) 11.0 (2.0–36.0) 11.0 (3.0–29.0) 11.0 (2.0–36.0)
Cycle 3 N = 61 N = 34 N = 27
Total Ovaleap® dose, IU
Mean (SD) 2113 (939) 1883 (687) 2402 (1132)
Median (range) 1875 (750–5400) 1800 (750–3450) 2100 (788–5400)
Duration of Ovaleap® stimulation, days
Mean (SD) 9.9 (1.7) 9.6 (1.7) 10.3 (1.7)
Median (range) 10.0 (5.0–14.0) 9.0 (5.0–13.0) 10.0 (7.0–14.0)
Number of oocytes retrievedb
Mean (SD) 13.5 (6.5) 12.3 (6.2) 15.0 (6.5)
Median (range) 12.0 (3.0–33.0) 11.0 (3.0–30.0) 12.0 (6.0–33.0)
SD standard deviation
aTotal Group N = 146; Ovaleap® N = 80; Gonal-f® N = 66
bTotal Group N = 60; Ovaleap® N = 33; Gonal-f® N = 27
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ceiving multiple IVF treatment cycles [23, 24] and
can be understood as being due to the poorer re-
sponse of these patients to FSH stimulation, as indi-
cated by not achieving pregnancy following the first
IVF cycle. However, the median total dose of Ovaleap®
in the current study was consistent with the Gonal-f®Table 4 Pregnancy rates
Total Group
Cycle 2
Biochemical pregnancy, n/N (%) 46/147 (31.0)
Ongoing pregnancya, n/N (%) 37/143 (25.9)
Cycle 3
Biochemical pregnancy, n/N (%) 19/61 (31.0)
Ongoing pregnancya, n/N (%) 13/60 (21.7)
Combined Cycles 2 and 3
Biochemical pregnancy, n/N (%) 63/147 (42.9)
Ongoing pregnancya, n/N (%) 50/144 (34.7)
aN includes only those patients with embryo transferdose used in other clinical trials for optimal follicular
development [15, 17–19]. Likewise, the biochemical
and ongoing pregnancy rates in the current study
were expected to be slightly lower than those found
in the Main Study as these patients did not become
pregnant in the initial IVF treatment cycle (ie, in the
Main study).Previous Treatment in Main Study
Ovaleap® Gonal-f®
24/80 (30.0) 22/67 (32.8)
21/79 (26.6) 16/64 (25.0)
10/34 (29.4) 9/27 (33.3)
8/33 (24.2) 5/27 (18.5)
33/80 (41.3) 30/67 (44.8)
29/80 (36.3) 21/64 (32.8)
Table 5 Main Study Inclusion and Exclusion Criteria for Selection
of Study Population
Inclusion Criteria
▪ Infertile but otherwise healthy women aged 18 to 37 years of any
racial origin
▪ Normal gonadotropic women with regular menstrual cycles of
21–35 days
▪ 2 confirmed normal ovaries and undergoing superovulation for ART
▪ BMI ≥18 kg/m2 and ≤29 kg/m2
▪ Basal FSH, estradiol, prolactin, and thyroid-stimulating hormone
concentrations in the normal range
Exclusion Criteria
▪ History of more than 2 previously completed consecutive unsuccessful
in vitro fertilization cycles; >3 miscarriages; history of a severe OHSS;
primary ovarian failure or being categorized as poor responders;
hypersensitivity or allergy to r-hFSH preparations; or neoplasm or history
of chemotherapy or radiation therapy
▪ Malformation of sexual organs incompatible with pregnancy or one
or both ovaries inaccessible for oocyte retrieval
▪ Administration of clomiphene or gonadotropins within 30 days prior
to enrollment
▪ Any significant cardiovascular, pulmonary, neurologic, endocrine,
hepatic, or renal disease
▪ After down-regulation prior to first administration of r-hFSH: serum
estradiol ≥50 pg/mL, ovarian cysts >10 mm (verified by ultrasound),
or a positive pregnancy test
ART assisted reproduction technology; BMI body mass index; FSH follicle-
stimulating hormone; OHSS ovarian hyperstimulation syndrome; r-hFSH
recombinant human follicle-stimulating hormone
Table 6 Distribution of Patients by Country
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ment options that are therapeutically equivalent in
terms of efficacy and safety to existing treatments,
with improved use convenience and high levels of
treatment-related patient satisfaction, may meet an
important need among infertile women using ART
[2]. Patient perceptions of their ovarian stimulation
treatment experience related to ease of use and
reduced dose variability have been shown to be
important in determining patient treatment prefer-
ence [25]. Additionally, use of pen devices and sim-
plification of injection procedures may be important
in determining patient treatment satisfaction and
preference [26]. Consistent with these treatment
needs, therapeutic equivalence has been shown
between Ovaleap® and Gonal-f® in the Main Study,
and patients have reported high satisfaction and
confidence in the dose preparation and injection
experience with the Ovaleap® pen device and rated
pen use as very convenient/convenient. These find-
ings support Ovaleap® as an important addition to
the ovarian stimulation treatment options for infer-
tile women using ART.
Limitations of the current study include the open-
label, uncontrolled study design; however, throughout
the follow-up study, the investigator and embryologist
remained blinded to the r-hFSH treatment received by
patients in the Main Study. Additionally, the study
analyses were descriptive and exploratory, with no
formal statistical tests planned or completed.
Generalization of the current study outcomes to other
patient populations should consider the leanness of
the included patients, as indicated by the mean body
mass index of 22 to 23 kg/m2. Additionally, further
research is necessary for evaluation of the safety and
efficacy of multiple treatment cycles of Ovaleap® in
ART, especially in older women.Previous Treatment in Main Study
Total Group Ovaleap® Gonal-f®
Cycle 2 N = 147 N = 80 N = 67
n (%) n (%)
Belgium + Germany 24 (16.3) 11 (13.8) 13 (19.4)
Czech Republic 28 (19.0) 16 (20.0) 12 (17.9)
Hungary 39 (26.5) 22 (27.5) 17 (25.4)
Poland 56 (38.1) 31 (38.8) 25 (37.3)
Cycle 3 N = 61 N = 34 N = 27
n (%) n (%)
Belgium + Germany 3 (4.9) 1 (2.9) 2 (7.4)
Czech Republic 8 (13.1) 6 (17.6) 2 (7.4)
Hungary 20 (32.8) 12 (35.3) 8 (29.6)
Poland 30 (49.2) 15 (44.1) 15 (55.6)Conclusions
Ovaleap® showed a favorable safety and tolerability
profile, comparable with Gonal-f®, following second
and third treatment cycles. There were no new or un-
expected safety findings. Efficacy endpoints in the
open-label follow-up study were consistent with those
found in the phase 3 randomized, controlled, assessor-
blinded, parallel-group Main Study. Level of satisfac-
tion with the Ovaleap® pen was very high. The findings
further support the safety and efficacy of Ovaleap® for
stimulation of follicular development in infertile
women undergoing ART, and they support continued
use of Ovaleap® for multiple cycles and a switch from
Gonal-f® to Ovaleap® if pregnancy is not achieved fol-
lowing the initial cycle.Appendix 1Appendix 2
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Previous Treatment in Main Study
MedDRA Preferred Term Total Group Ovaleap® Gonal-f®
N = 147 N = 80 N = 67
n (%) n (%) n (%)
Any TEAE 19 (12.9) 9 (11.3) 10 (14.9)
Abdominal pain lower 1 (0.7) 0 1 (1.5)
Anemia 1 (0.7) 0 1 (1.5)
Appendicitis 1 (0.7) 0 1 (1.5)
Application site erythema 1 (0.7) 1 (1.3) 0
Application site hematoma 1 (0.7) 0 1 (1.5)
Application site pruritus 1 (0.7) 1 (1.3) 0
Back pain 1 (0.7) 1 (1.3) 0
Borderline ovarian tumor 1 (0.7) 1 (1.3) 0
Cyst aspiration 1 (0.7) 0 1 (1.5)
Depressed mood 1 (0.7) 0 1 (1.5)
Influenza-like illness 1 (0.7) 1 (1.3) 0
Injection-site erythema 1 (0.7) 0 1 (1.5)
Injection-site pruritus 1 (0.7) 0 1 (1.5)
Menorrhagia 1 (0.7) 1 (1.3) 0
Metrorrhagia 1 (0.7) 1 (1.3) 0
Muscle spasms 1 (0.7) 1 (1.3) 0
Nausea 1 (0.7) 0 1 (1.5)
OHSS 1 (0.7) 0 1 (1.5)
Procedural pain 1 (0.7) 0 1 (1.5)
Pyrexia 1 (0.7) 1 (1.3) 0
Respiratory tract inflammation 1 (0.7) 0 1 (1.5)
Sinusitis 1 (0.7) 0 1 (1.5)
Upper respiratory tract infection 1 (0.7) 1 (1.3) 0
Vaginal discharge 1 (0.7) 1 (1.3) 0
Vaginal infection 2 (1.4) 2 (2.5) 0
Vulvovaginal pruritus 1 (0.7) 1 (1.3) 0
OHSS ovarian hyperstimulation syndrome; TEAE treatment-emergent adverse event
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Previous Treatment in Main Study
Total Group Ovaleap® Gonal-f®
Cycle 2 N = 146 N = 80 N = 66
Number of follicles >14 mm
Mean (SD) 10.0 (5.6) 9.3 (4.8) 10.9 (6.4)
Median (range) 9.0 (0.0–32.0) 9.0 (0.0–31.0) 10.0 (0.0–32.0)
Cycle 3 N = 60 N = 33 N = 27
Number of follicles >14 mm
Mean (SD) 11.9 (5.4) 10.8 (4.9) 13.3 (5.8)
Median (range) 11.0 (0.0–26.0) 11.0 (0.0–22.0) 11.0 (7.0–26.0)
hCG human chorionic gonadotropin; SD standard deviationAppendix 5Table 9 Oocyte Quality
Previous Treatment in Main Study
Total Group Ovaleap® Gonal-f®
Cycle 2 N = 146 N = 80 N = 66
Oocyte quality, n (%) oocytes
Z1 (Best) 162 (18.4) 87 (17.6) 75 (19.3)
Z2 363 (41.2) 210 (42.6) 153 (39.4)
Z3 234 (26.6) 129 (26.2) 105 (27.1)
Z4 (Worst) 122 (13.8) 67 (13.6) 55 (14.2)
Total 2 PN oocytes 881 (100.0) 493 (100.0) 388 (100.0)
Cycle 3 N = 60 N = 33 N = 27
Oocyte quality, n (%) oocytes
Z1 (Best) 71 (17.4) 34 (15.7) 37 (19.5)
Z2 160 (39.3) 84 (38.7) 76 (40.0)
Z3 127 (31.2) 68 (31.3) 59 (31.1)
Z4 (Worst) 49 (12.0) 31 (14.3) 18 (9.5)
Total 2 PN oocytes 407 (100.0) 217 (100.0) 190 (100.0)
PN pronucleus; Z score zygote scoring system of Scott et al. [10]
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ART: assisted reproductive technology; AUC0-t: area under the concentration-
time curve; Cmax: peak plasma concentration; GnRH: gonadotropin-releasing
hormone; hCG: human chorionic gonadotropin; IVF: in vitro fertilization;
OHSS: ovarian hyperstimulation syndrome; PN: pronucleus; r-hFSH: recombinant
human follicle-stimulating hormone; SC: subcutaneous; TEADR: treatment-
emergent adverse drug reaction; TEAE: treatment-emergent adverse event.
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